Gapping down
M&A news:
- DD -10.8% (DuPont announced it is completing today the merger of IFF and Nutrition & Biosciences; has concluded the strategic review of its Non-Core businesses)
- HZNP -1.0% (Viela Bio to be acquired by Horizon Therapeutics (HZNP) for $53.00 per share in cash)
Other news:
- CNCE -50% (Phase 2 clinical trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint or other secondary endpoints)
- NNOX -8% (received additional information request from FDA in connection with its review of Nanox.ARC)
- VXX -5.7% (trading lower in response to rebound in US futures)
- EXPR -5% (continued volatility in pre-mkt)
- GME -1.9% (continued volatility in pre-mkt)
- ALRN -1.6% (files for 9 mln share common stock offering by selling shareholders)
- ID -1.1% (files for 30,206,509 share common stock offering by selling shareholders)
Analyst comments:
- GSX -3.8% (downgraded to Underweight from Neutral at JP Morgan)
- GOGO -3.1% (downgraded to Underweight from Neutral at JP Morgan)
- CMBM -2.1% (downgraded to Mkt Perform from Outperform at Raymond James)
- FTI -2.1% (downgraded to Hold from Buy at Berenberg)
- PSO -1.3% (downgraded to Sell from Buy at UBS)
- WSM -0.7% (downgraded to Sell from Neutral at UBS)